CANbridge Starts Neuromuscular Gene Therapy Program with UMass

CANbridge Pharma of Beijing has formed a second gene therapy collaboration with the Horae Gene Therapy Center at the University of Massachusetts Medical School. The latest sponsored research program will develop novel customized adeno-associated virus (AAV) vectors aimed at neuromuscular diseases. The program will be directed by Miguel Sena-Esteves, PhD, Associate Professor of Neurology at the UMass Medical School , Earlier this year, CANbridge formed a collaboration with Guangping Gao, PhD, Director of the Horae Center to study gene therapy-based treatments for rare diseases. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.